Understanding the p-Toluenesulfonamide/Triphenylphosphine Oxide Crystal Chemistry: A New 1:1 Cocrystal and Ternary Phase Diagram

Typeset version

 

TY  - JOUR
  - Croker, DM,Foreman, ME,Hogan, BN,Maguire, NM,Elcoate, CJ,Hodnett, BK,Maguire, AR,Rasmuson, AC,Lawrence, SE
  - 2012
  - January
  - Crystal Growth ; Design
  - Understanding the p-Toluenesulfonamide/Triphenylphosphine Oxide Crystal Chemistry: A New 1:1 Cocrystal and Ternary Phase Diagram
  - Validated
  - ()
  - PHARMACEUTICAL COCRYSTALS CO-CRYSTALS
  - 12
  - 869
  - 875
  - A novel 1:1 cocrystal between p-toluenesulfonamide and triphenylphosphine oxide has been prepared and structurally characterized. This 1:1 cocrystal was observed to form during solid state grinding experiments, with subsequent formation of a known 3:2 cocrystal in the presence of excess sulfonamide. Both cocrystals are stable in the solid state. The ternary phase diagram for the two coformers was constructed in two different solvents: acetonitrile and dichloromethane. Examination of these diagrams clarified solution crystallization of both the newly discovered 1:1 cocrystal and the previously reported 3:2 cocrystal, and identified regions of stability for each cocrystal in each solvent. The choice of solvent was found to have a significant effect on the position of the solid state regions within a cocrystal system.
  - DOI 10.1021/cg201300e
DA  - 2012/01
ER  - 
@article{V160748018,
   = {Croker,  DM and Foreman,  ME and Hogan,  BN and Maguire,  NM and Elcoate,  CJ and Hodnett,  BK and Maguire,  AR and Rasmuson,  AC and Lawrence,  SE },
   = {2012},
   = {January},
   = {Crystal Growth ; Design},
   = {Understanding the p-Toluenesulfonamide/Triphenylphosphine Oxide Crystal Chemistry: A New 1:1 Cocrystal and Ternary Phase Diagram},
   = {Validated},
   = {()},
   = {PHARMACEUTICAL COCRYSTALS CO-CRYSTALS},
   = {12},
  pages = {869--875},
   = {{A novel 1:1 cocrystal between p-toluenesulfonamide and triphenylphosphine oxide has been prepared and structurally characterized. This 1:1 cocrystal was observed to form during solid state grinding experiments, with subsequent formation of a known 3:2 cocrystal in the presence of excess sulfonamide. Both cocrystals are stable in the solid state. The ternary phase diagram for the two coformers was constructed in two different solvents: acetonitrile and dichloromethane. Examination of these diagrams clarified solution crystallization of both the newly discovered 1:1 cocrystal and the previously reported 3:2 cocrystal, and identified regions of stability for each cocrystal in each solvent. The choice of solvent was found to have a significant effect on the position of the solid state regions within a cocrystal system.}},
   = {DOI 10.1021/cg201300e},
  source = {IRIS}
}
AUTHORSCroker, DM,Foreman, ME,Hogan, BN,Maguire, NM,Elcoate, CJ,Hodnett, BK,Maguire, AR,Rasmuson, AC,Lawrence, SE
YEAR2012
MONTHJanuary
JOURNAL_CODECrystal Growth ; Design
TITLEUnderstanding the p-Toluenesulfonamide/Triphenylphosphine Oxide Crystal Chemistry: A New 1:1 Cocrystal and Ternary Phase Diagram
STATUSValidated
TIMES_CITED()
SEARCH_KEYWORDPHARMACEUTICAL COCRYSTALS CO-CRYSTALS
VOLUME12
ISSUE
START_PAGE869
END_PAGE875
ABSTRACTA novel 1:1 cocrystal between p-toluenesulfonamide and triphenylphosphine oxide has been prepared and structurally characterized. This 1:1 cocrystal was observed to form during solid state grinding experiments, with subsequent formation of a known 3:2 cocrystal in the presence of excess sulfonamide. Both cocrystals are stable in the solid state. The ternary phase diagram for the two coformers was constructed in two different solvents: acetonitrile and dichloromethane. Examination of these diagrams clarified solution crystallization of both the newly discovered 1:1 cocrystal and the previously reported 3:2 cocrystal, and identified regions of stability for each cocrystal in each solvent. The choice of solvent was found to have a significant effect on the position of the solid state regions within a cocrystal system.
PUBLISHER_LOCATION
ISBN_ISSN
EDITION
URL
DOI_LINKDOI 10.1021/cg201300e
FUNDING_BODY
GRANT_DETAILS